Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 36, Issue 6, 2005, Pages 511-516

  Svahn, Britt Marie ^a   Ringden O ^a   Remberger, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Protective care; Quality of life; Stem cell transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; BUSULFAN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; GASTROINTESTINAL INFECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES SIMPLEX; HOME CARE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LONG TERM CARE; MORTALITY; PANCYTOPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROBABILITY; RELAPSE; SURVIVAL RATE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PANCYTOPENIA; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 31044441787     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705096     Document Type: Article

References (39)

1. Storb R, Thomas ED. Allogeneic bone-marrow transplantation. Immunol Rev 1983; 71: 77-102.
2. Meyers JD, Thomas ED. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS (eds). Clinical Approach to Infection in the Immunocompromised Host. Alan R Liss Inc.: New York, 1983, pp 525-556.
3. Atkinson K, Singhal S. Bacterial infections. In: Atkinson, K (ed.). Clinical Bone Marrow and Blood Stem Cell Transplantation, 2nd edn. Cambridge University Press: Cambridge, UK, 2000, p 716.
4. Tollemar J, Ringdén O, Boström L et al. Variables predicting deep fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 635-641.
5. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis 2001; 33: 947-953.
6. Sparrelid E, Hägglund H, Remberger M et al. Bactaeremia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection. Bone Marrow Transplant 1998; 22: 795-800.
7. Buckner CD, Clift RA, Sanders JE et al. Protective environment for marrow transplant recipients. A prospective study. Ann Int Med 1978; 89: 893-901.
8. Navari RM, Buckner CD, Clift RA et al. Prophylaxis of infections in patients with aplastic anemia receiving allogeneic marrow transplants. Am J Med 1984; 76: 564-572.
9. Sherertz RJ, Belani A, Kramer BS et al. Impact of air filtration on nosocomial Aspergillus infections: Unique risk or bone marrow transplant recipients. Am J Med 1987; 83: 709-718.
10. Dykewicz CA, Jaffe HW, Kaplan JE, in collaboration with The Guidelines Working Group from the CDC, the Infectious Disease Society of America and the American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among haematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 659-737.
11. Passweg JR, Rowlings PA, Atkinson KA et al. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant 1998; 21: 1231-1238.
12. Svahn B-M, Bjurman B, Myrbäck KE et al. Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? - A preliminary report. Bone Marrow Transplant 2000; 26: 1057-1060.
13. Svahn B-M, Remberger M, Myrbäck K-E et al. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared to hospital care. Blood 2002; 100: 4317-4324.
14. Weiden PL, Sullivan KM, Fluornoy N et al. Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304: 1529-1533.
15. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions following bone marrow transplantation in humans. Blood 1989; 75: 555-562.
16. Ringdén O, Labopin M, Gluckman E et al. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Bone Marrow Transplant 1996; 18: 921-929.
17. Storb R, Prentice RL, Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Int Med 1983; 98: 461-466.
18. Ringdén O, Paulin T, Lönnqvist B, Nilsson B. An analysis of factors predisposing for chronic graft-versus-host disease. Exp Hematol 1985; 13: 1062-1067.
19. Atkinson K, Horowitz MM, Van Bekkum DW et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990; 75: 2459-2464.
20. Ringdén O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995; 15: 619-625.
21. Ringdén O, Ruutu T, Remberger M et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukaemia. A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
22. Hassan M, Ljungman P, Bolme P et al. Busulphan bioavailability. Blood 1994; 84: 2144-2150.
23. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cyto-reduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998; 91: 756-763.
24. Remberger M, Svahn B-M, Hentschke P et al. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823-830.
25. Lundgren G, Wilczek H, Lönnqvist B et al. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis 1985; 47: 137-144.
26. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine vs cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukaemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
27. Remberger M, Naseh N, Aschan J et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV. Bone Marrow Transplant 2003; 32: 217-223.
28. Ringdén O, Labopin M, Gorin N-C et al, for the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukaemia increases the risk of graft-versus-host disease and death. J Clin Oncol 2004; 22: 416-423.
29. van Bekkum DW, Knaan S. A role of bacterial microflora in development of intestinal lesions from graft versus host reactions. J Natl Cancer Inst 1977; 58: 787-789.
30. Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiat Res 1971; 45: 577-588.
31. Boström L, Ringdén O, Sundberg B et al. Pretransplant herpes virus serology and acute graft-versus-host disease. Transplantation 1988; 46: 548-552.
32. Storb R, Prentice RL, Buckner CD et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings: Beneficial effects of a protective environment. N Engl J Med 1983; 308: 302-307.
33. Russell JA, Poon M-C, Jones AR et al. Allogeneic bone-marrow transplantation without protective isolation in adults with malignant disease. Lancet 1992; 339: 38-40.
34. Ferrara JLM, Reddy P. Immunobiology of acute graft-versus-host disease. Blood Rev 2003; 17: 187-194.
35. Ringdén O, Hermans J, Labopin M et al, for the Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Leukemia Lymphoma 1996; 24: 71-79.
36. Gratwohl A, Hermans J, Apperley J et al. Acute graft-versus-host disease: Grade and outcome in patients with chronic myelogenous leukemia. Blood 1995; 86: 813-818.
37. Carlens S, Aschan J, Remberger M et al. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia. Bone Marrow Transplant 1999; 24: 629-635.
38. Marmont AM, Horowitz MM, Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
39. Aschan J, Ringdén O, Sundberg B et al. Methotrexate combined with cyclosporine A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113-119.